| Literature DB >> 24682005 |
S Colak1, C D Zimberlin1, E Fessler1, L Hogdal2, P R Prasetyanti1, C M Grandela3, A Letai2, J P Medema1.
Abstract
Tumor heterogeneity is in part determined by the existence of cancer stem cells (CSCs) and more differentiated tumor cells. CSCs are considered to be the tumorigenic root of cancers and suggested to be chemotherapy resistant. Here we exploited an assay that allowed us to measure chemotherapy-induced cell death in CSCs and differentiated tumor cells simultaneously. This confirmed that CSCs are selectively resistant to conventional chemotherapy, which we revealed is determined by decreased mitochondrial priming. In agreement, lowering the anti-apoptotic threshold using ABT-737 and WEHI-539 was sufficient to enhance chemotherapy efficacy, whereas ABT-199 failed to sensitize CSCs. Our data therefore point to a crucial role of BCLXL in protecting CSCs from chemotherapy and suggest that BH3 mimetics, in combination with chemotherapy, can be an efficient way to target chemotherapy-resistant CSCs.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24682005 PMCID： PMC4207483 DOI： 10.1038/cdd.2014.37
Source DB: PubMed Journal: Cell Death Differ ISSN： 1350-9047 Impact factor: 15.828